Intelligent Bio Solutions Inc (NASDAQ: INBS) is a medical device company that develops and sells non-invasive, fingerprint sweat-based drug screening products. Revenue comes from transactional sales of the Intelligent Fingerprinting Drug Screening System, a two-part kit consisting of a single-use cartridge and a portable handheld reader, with optional confirmatory samples sent to third-party laboratory service providers. The IFP System is commercially available in select markets outside the United States, as of the 10-K filed August 15, 2025. INBS sells into safety-critical industries including construction, transportation and logistics, mining, manufacturing, engineering, drug rehabilitation organizations, and judicial organizations. The company is headquartered in New York City, with two U.S. employees operating from a shared office space, as of the filing date. INBS has not paid any dividends and has raised capital through an at-the-market equity offering, raising approximately $2.25 million net between September 18, 2024, and June 30, 2025.

Revenue model

Transactional product sales of single-use drug screening cartridges and portable handheld readers. Confirmatory testing samples are routed to third-party laboratory providers. Distribution relies in part on third-party distributors in international markets.

Products and services

Intelligent Fingerprinting Drug Screening System (IFP System): a two-part kit comprising a tamper-evident cartridge that collects ten fingerprint sweat samples in under one minute and a portable reader that delivers on-screen results in under ten minutes. Detects opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. Confirmatory kits can be sent to third-party laboratories for confirmation testing.

Customers and end markets

Safety-critical industries: construction, transportation and logistics, mining, manufacturing, and engineering. Drug treatment organizations in the rehabilitation sector. Judicial organizations. As of August 12, 2025, there were approximately 485 holders of record of INBS common stock.

Value-chain role

Medical device manufacturer and distributor. Designs and sells the IFP System hardware and consumable cartridges. Relies on third-party distributors for international sales and marketing, and on third-party laboratory service providers for confirmatory testing.

Geographic exposure

IFP System is commercially available in certain countries outside the United States as of the filing date. U.S. operations consist of a small shared office in New York City with two employees. The company targets global expansion of the IFP System.

Source: SEC 10-K, filed 2025-08-15

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories ALLIED HEALTHCARE PRODUCTS INC MICRON SOLUTIONS INC /DE/ ThermoGenesis Holdings, Inc. Nuwellis Inc INVIVO THERAPEUTICS HOLDINGS CORP. Motus GI Holdings, Inc. ENCISION INC Vyome Holdings Inc